直接口服抗凝血药物在骨髓增殖性肿瘤患者血栓防治中的应用  

Application of direct oral anticoagulants in the prevention and treatment of thrombosis in patients with myeloproliferative neoplasms

作　　者：冯秋天 黄健[2] FENG Qiu-tian;HUANG Jian(Department of Hematology,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Yiwu 322000,China;不详)

机构地区：[1]浙江大学医学院附属第四医院血液内科,浙江义乌322000 [2]浙江大学医学院附属第一医院血液科,杭州310003

出　　处：《医师在线》2024年第5期84-87,共4页Journal of Doctors Online

基　　金：浙江省医学会临床医学科研专项资金项目(2022ZYC-D09);浙江省科技计划项目(2022C03137);浙江省基础公益研究计划项目(LGF21H080003);金华市科学技术研究计划项目(2020-3-011)。

摘　　要：骨髓增殖性肿瘤(MPN)是一组由于造血干细胞增殖异常而引起的疾病,包括骨髓纤维化(MF)、真性红细胞增多症(PV)和原发性血小板增多症(ET)。MPN患者常伴随高血液黏稠度,增加了血栓形成的风险,因此抗凝治疗成为MPN管理中不可或缺的一部分。直接口服抗凝血药物(DOAC)作为一类新型抗凝药物,近年来在血栓防治中的应用逐渐引起关注。本综述将详细探讨DOAC在MPN患者血栓防治中的应用现状、优势与不足、临床研究进展以及未来发展方向。Myeloproliferative neoplasms(MPN)comprise a group of disorders caused by abnormal proliferation of hematopoietic stem cells,including myelofibrosis(MF),polycythemia vera(PV),and essential thrombocythemia(ET).Patients with MPN often experience increased blood viscosity and an elevated risk of thrombosis.Therefore,anticoagulant therapy has become an indispensable component of MPN management.Direct oral anticoagulants(DOAC),as a novel class of anticoagulants,have gained attention in recent years for their application in thrombosis prevention and treatment.This review will delve into the current status,advantages and disadvantages,clinical research progress,and future directions of DOAC in thrombosis prevention and treatment for MPN patients.

关 键 词：直接口服抗凝血药物 骨髓增殖性肿瘤 血栓防治 

分 类 号：R73[医药卫生—肿瘤]